Ach-Methotrexate: Formulary list price $0.2513/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2513 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99838 · Verify on the e-Formulary ↗ (DIN 02509067)
Source record
DIN 02509067: Ach-Methotrexate
Raw flags: sec3=Y
Item: 100000001; group id 175; item number 0316; lccId None; manufacturer id ACH
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $0.2513; ministry $0.2513
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02509067
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99838Interchangeable products
Apo-Methotrexate · DIN 02182963 · $0.2513
Auro-Methotrexate · DIN 02524023 · $0.2513
M-Methotrexate · DIN 02534916 · $0.2513
PMS-Methotrexate · DIN 02170698 · $0.2513
Shortage status: resolved shortage (ended 2026-02-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02509067
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Methotrexate · DIN 02182963 · 2.5mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Methotrexate · DIN 02182963
Manufacturer: Apotex Inc.; listing date 2001-10-11
Health Canada: Marketed since 2021-07-22 · brand APO-METHOTREXATE · ATC L01BA01 METHOTREXATE · form Tablet · route Oral · ingredients METHOTREXATE (METHOTREXATE DISODIUM) 2.5 MG · company Apotex inc · schedule Prescription
Apo-Methotrexate: Formulary list price $0.2513/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2513 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=44263 · Verify on the e-Formulary ↗ (DIN 02182963)
Source record
DIN 02182963: Apo-Methotrexate
Raw flags: sec3=Y
Item: 100000001; group id 175; item number 0316; lccId None; manufacturer id APX
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $0.2513; ministry $0.2513
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02182963
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=44263Interchangeable products
Ach-Methotrexate · DIN 02509067 · $0.2513
Auro-Methotrexate · DIN 02524023 · $0.2513
M-Methotrexate · DIN 02534916 · $0.2513
PMS-Methotrexate · DIN 02170698 · $0.2513
Shortage status: resolved shortage (ended 2025-07-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02182963
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Methotrexate · DIN 02524023 · 2.5mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Methotrexate · DIN 02524023
Manufacturer: Auro Pharma Inc.; listing date 2023-03-31
Health Canada: Marketed since 2023-02-02 · brand AURO-METHOTREXATE · ATC L04AX03 METHOTREXATE · form Tablet · route Oral · ingredients METHOTREXATE (METHOTREXATE DISODIUM) 2.5 MG · company Auro pharma inc · schedule Prescription
Auro-Methotrexate: Formulary list price $0.2513/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2513 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101306 · Verify on the e-Formulary ↗ (DIN 02524023)
Source record
DIN 02524023: Auro-Methotrexate
Raw flags: sec3=Y
Item: 100000001; group id 175; item number 0316; lccId None; manufacturer id AUR
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $0.2513; ministry $0.2513
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02524023
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101306Interchangeable products
Ach-Methotrexate · DIN 02509067 · $0.2513
Apo-Methotrexate · DIN 02182963 · $0.2513
M-Methotrexate · DIN 02534916 · $0.2513
PMS-Methotrexate · DIN 02170698 · $0.2513
Shortage status: resolved shortage (ended 2025-08-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02524023
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Methotrexate · DIN 02534916 · 2.5mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
M-Methotrexate · DIN 02534916
Manufacturer: Mantra Pharma Inc.; listing date 2024-06-28
Health Canada: Marketed since 2024-04-24 · brand M-METHOTREXATE · ATC L01BA01 METHOTREXATE · form Tablet · route Oral · ingredients METHOTREXATE (METHOTREXATE DISODIUM) 2.5 MG · company Mantra pharma inc · schedule Prescription
M-Methotrexate: Formulary list price $0.2513/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2513 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102380 · Verify on the e-Formulary ↗ (DIN 02534916)
Source record
DIN 02534916: M-Methotrexate
Raw flags: sec3=Y
Item: 100000001; group id 175; item number 0316; lccId None; manufacturer id MAT
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $0.2513; ministry $0.2513
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02534916
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102380Interchangeable products
Ach-Methotrexate · DIN 02509067 · $0.2513
Apo-Methotrexate · DIN 02182963 · $0.2513
Auro-Methotrexate · DIN 02524023 · $0.2513
PMS-Methotrexate · DIN 02170698 · $0.2513
Shortage status: resolved shortage (ended 2026-03-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02534916
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Methotrexate · DIN 02170698 · 2.5mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Methotrexate · DIN 02170698
Manufacturer: Pharmascience Inc.; listing date 1997-02-04
Health Canada: Marketed since 2018-10-04 · brand PMS-METHOTREXATE · ATC L01BA01 METHOTREXATE · form Tablet · route Oral · ingredients METHOTREXATE (METHOTREXATE DISODIUM) 2.5 MG · company Pharmascience inc · schedule Prescription
PMS-Methotrexate: Formulary list price $0.2513/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2513 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=44161 · Verify on the e-Formulary ↗ (DIN 02170698)
Source record
DIN 02170698: PMS-Methotrexate
Raw flags: sec3=Y
Item: 100000001; group id 175; item number 0316; lccId None; manufacturer id PMS
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $0.2513; ministry $0.2513
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02170698
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=44161Interchangeable products
Ach-Methotrexate · DIN 02509067 · $0.2513
Apo-Methotrexate · DIN 02182963 · $0.2513
Auro-Methotrexate · DIN 02524023 · $0.2513
M-Methotrexate · DIN 02534916 · $0.2513
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02170698
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Methotrexate Subcutaneous · DIN 02491281
Manufacturer: Accord Healthcare Inc.; listing date 2025-12-30
Health Canada: Marketed since 2025-10-20 · brand METHOTREXATE SUBCUTANEOUS · ATC L04AX03 METHOTREXATE · form Solution · route Subcutaneous · ingredients METHOTREXATE (METHOTREXATE SODIUM) 10 MG/0.2ML · company Accord healthcare inc · schedule Prescription
Methotrexate Subcutaneous: Formulary list price $14.8200/unit (unit not stated in source; not the patient's cost)
Ministry pays: $14.8200 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98130 · Verify on the e-Formulary ↗ (DIN 02491281)
Source record
DIN 02491281: Methotrexate Subcutaneous
Raw flags: sec3=Y
Item: 100000302; group id 175; item number 0309; lccId None; manufacturer id ACH
Source form: Inj Sol-Pref Syr; strength: 10mg/0.2mL
Recorded listing: General benefit
Source prices (unrounded): $14.8200; ministry $14.8200
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02491281
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98130Interchangeable products
Metoject Subcutaneous · DIN 02454831 · $14.8200
PMS-Methotrexate Injection · DIN 02539608 · $14.8200
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02491281
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94161 · Verify on the e-Formulary ↗ (DIN 02454831)
Source record
DIN 02454831: Metoject Subcutaneous
Raw flags: sec3=Y
Item: 100000302; group id 175; item number 0309; lccId None; manufacturer id MDX
Source form: Inj Sol-Pref Syr; strength: 10mg/0.2mL
Recorded listing: General benefit
Source prices (unrounded): $16.3000; ministry $14.8200
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02454831
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94161Interchangeable products
Methotrexate Subcutaneous · DIN 02491281 · $14.8200
PMS-Methotrexate Injection · DIN 02539608 · $14.8200
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02454831
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Methotrexate Injection · DIN 02539608
Manufacturer: Pharmascience Inc.; listing date 2024-05-31
Health Canada: Marketed since 2024-03-14 · brand PMS-METHOTREXATE INJECTION · ATC L04AX03 METHOTREXATE · form Solution · route Subcutaneous · ingredients METHOTREXATE (METHOTREXATE SODIUM) 10 MG/0.2ML · company Pharmascience inc · schedule Prescription
PMS-Methotrexate Injection: Formulary list price $14.8200/unit (unit not stated in source; not the patient's cost)
Ministry pays: $14.8200 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102835 · Verify on the e-Formulary ↗ (DIN 02539608)
Source record
DIN 02539608: PMS-Methotrexate Injection
Raw flags: sec3=Y
Item: 100000302; group id 175; item number 0309; lccId None; manufacturer id PMS
Source form: Inj Sol-Pref Syr; strength: 10mg/0.2mL
Recorded listing: General benefit
Source prices (unrounded): $14.8200; ministry $14.8200
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02539608
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102835Interchangeable products
Methotrexate Subcutaneous · DIN 02491281 · $14.8200
Metoject Subcutaneous · DIN 02454831 · $14.8200
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02539608
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Methotrexate Subcutaneous · DIN 02491303
Manufacturer: Accord Healthcare Inc.; listing date 2025-12-30
Health Canada: Marketed since 2025-10-20 · brand METHOTREXATE SUBCUTANEOUS · ATC L04AX03 METHOTREXATE · form Solution · route Subcutaneous · ingredients METHOTREXATE (METHOTREXATE SODIUM) 12.5 MG/0.25ML · company Accord healthcare inc · schedule Prescription
Methotrexate Subcutaneous: Formulary list price $15.6000/unit (unit not stated in source; not the patient's cost)
Ministry pays: $15.6000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98131 · Verify on the e-Formulary ↗ (DIN 02491303)
Source record
DIN 02491303: Methotrexate Subcutaneous
Raw flags: sec3=Y
Item: 100000303; group id 175; item number 0310; lccId None; manufacturer id ACH
Source form: Inj Sol-Pref Syr; strength: 12.5mg/0.25mL
Recorded listing: General benefit
Source prices (unrounded): $15.6000; ministry $15.6000
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02491303
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98131Interchangeable products
Metoject Subcutaneous · DIN 02454750 · $15.6000
PMS-Methotrexate Injection · DIN 02539616 · $15.6000
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02491303
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94144 · Verify on the e-Formulary ↗ (DIN 02454750)
Source record
DIN 02454750: Metoject Subcutaneous
Raw flags: sec3=Y
Item: 100000303; group id 175; item number 0310; lccId None; manufacturer id MDX
Source form: Inj Sol-Pref Syr; strength: 12.5mg/0.25mL
Recorded listing: General benefit
Source prices (unrounded): $17.1600; ministry $15.6000
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02454750
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94144Interchangeable products
Methotrexate Subcutaneous · DIN 02491303 · $15.6000
PMS-Methotrexate Injection · DIN 02539616 · $15.6000
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02454750
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Methotrexate Injection · DIN 02539616
Manufacturer: Pharmascience Inc.; listing date 2024-05-31
Health Canada: Marketed since 2024-03-14 · brand PMS-METHOTREXATE INJECTION · ATC L04AX03 METHOTREXATE · form Solution · route Subcutaneous · ingredients METHOTREXATE (METHOTREXATE SODIUM) 12.5 MG/0.25ML · company Pharmascience inc · schedule Prescription
PMS-Methotrexate Injection: Formulary list price $15.6000/unit (unit not stated in source; not the patient's cost)
Ministry pays: $15.6000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102836 · Verify on the e-Formulary ↗ (DIN 02539616)
Source record
DIN 02539616: PMS-Methotrexate Injection
Raw flags: sec3=Y
Item: 100000303; group id 175; item number 0310; lccId None; manufacturer id PMS
Source form: Inj Sol-Pref Syr; strength: 12.5mg/0.25mL
Recorded listing: General benefit
Source prices (unrounded): $15.6000; ministry $15.6000
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02539616
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102836Interchangeable products
Methotrexate Subcutaneous · DIN 02491303 · $15.6000
Metoject Subcutaneous · DIN 02454750 · $15.6000
Shortage status: resolved shortage (ended 2025-03-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02539616
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Methotrexate Subcutaneous: Formulary list price $16.3800/unit (unit not stated in source; not the patient's cost)
Ministry pays: $16.3800 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98132 · Verify on the e-Formulary ↗ (DIN 02491311)
Source record
DIN 02491311: Methotrexate Subcutaneous
Raw flags: sec3=Y
Item: 100000292; group id 175; item number 0311; lccId None; manufacturer id ACH
Source form: Inj Sol-Pref Syr; strength: 15mg/0.3mL
Recorded listing: General benefit
Source prices (unrounded): $16.3800; ministry $16.3800
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02491311
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98132Interchangeable products
Metoject Subcutaneous · DIN 02454858 · $16.3800
PMS-Methotrexate Injection · DIN 02539624 · $16.3800
Shortage status: resolved shortage (ended 2025-05-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02491311
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Metoject Subcutaneous: Formulary list price $16.3800/unit (unit not stated in source; not the patient's cost)
Ministry pays: $16.3800 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94162 · Verify on the e-Formulary ↗ (DIN 02454858)
Source record
DIN 02454858: Metoject Subcutaneous
Raw flags: sec3=Y
Item: 100000292; group id 175; item number 0311; lccId None; manufacturer id MDX
Source form: Inj Sol-Pref Syr; strength: 15mg/0.3mL
Recorded listing: General benefit
Source prices (unrounded): $16.3800; ministry $16.3800
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02454858
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94162Interchangeable products
Methotrexate Subcutaneous · DIN 02491311 · $16.3800
PMS-Methotrexate Injection · DIN 02539624 · $16.3800
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02454858
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Methotrexate Injection: Formulary list price $16.3800/unit (unit not stated in source; not the patient's cost)
Ministry pays: $16.3800 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102837 · Verify on the e-Formulary ↗ (DIN 02539624)
Source record
DIN 02539624: PMS-Methotrexate Injection
Raw flags: sec3=Y
Item: 100000292; group id 175; item number 0311; lccId None; manufacturer id PMS
Source form: Inj Sol-Pref Syr; strength: 15mg/0.3mL
Recorded listing: General benefit
Source prices (unrounded): $16.3800; ministry $16.3800
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02539624
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102837Interchangeable products
Methotrexate Subcutaneous · DIN 02491311 · $16.3800
Metoject Subcutaneous · DIN 02454858 · $16.3800
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02539624
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Methotrexate Subcutaneous: Formulary list price $16.0000/unit (unit not stated in source; not the patient's cost)
Ministry pays: $16.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98133 · Verify on the e-Formulary ↗ (DIN 02491338)
Source record
DIN 02491338: Methotrexate Subcutaneous
Raw flags: sec3=Y
Item: 100000275; group id 175; item number 0312; lccId None; manufacturer id ACH
Source form: Inj Sol-Pref Syr; strength: 17.5mg/0.35mL
Recorded listing: General benefit
Source prices (unrounded): $16.0000; ministry $16.0000
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02491338
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98133Interchangeable products
Metoject Subcutaneous · DIN 02454769 · $16.0000
PMS-Methotrexate Injection · DIN 02539632 · $16.0000
Shortage status: resolved shortage (ended 2025-10-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02491338
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Metoject Subcutaneous: Formulary list price $16.0000/unit (unit not stated in source; not the patient's cost)
Ministry pays: $16.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94145 · Verify on the e-Formulary ↗ (DIN 02454769)
Source record
DIN 02454769: Metoject Subcutaneous
Raw flags: sec3=Y
Item: 100000275; group id 175; item number 0312; lccId None; manufacturer id MDX
Source form: Inj Sol-Pref Syr; strength: 17.5mg/0.35mL
Recorded listing: General benefit
Source prices (unrounded): $16.0000; ministry $16.0000
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02454769
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94145Interchangeable products
Methotrexate Subcutaneous · DIN 02491338 · $16.0000
PMS-Methotrexate Injection · DIN 02539632 · $16.0000
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02454769
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Methotrexate Injection: Formulary list price $16.0000/unit (unit not stated in source; not the patient's cost)
Ministry pays: $16.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102838 · Verify on the e-Formulary ↗ (DIN 02539632)
Source record
DIN 02539632: PMS-Methotrexate Injection
Raw flags: sec3=Y
Item: 100000275; group id 175; item number 0312; lccId None; manufacturer id PMS
Source form: Inj Sol-Pref Syr; strength: 17.5mg/0.35mL
Recorded listing: General benefit
Source prices (unrounded): $16.0000; ministry $16.0000
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02539632
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102838Interchangeable products
Methotrexate Subcutaneous · DIN 02491338 · $16.0000
Metoject Subcutaneous · DIN 02454769 · $16.0000
Shortage status: resolved shortage (ended 2025-11-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02539632
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Methotrexate Sodium: Formulary list price $12.7375/unit (unit not stated in source; not the patient's cost)
Ministry pays: $12.7375 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=44261 · Verify on the e-Formulary ↗ (DIN 02182947)
Source record
DIN 02182947: Methotrexate Sodium
Raw flags: sec3=Y
Item: 100000054; group id 175; item number 0307; lccId None; manufacturer id MAY
Source form: Inj Sol-2mL Pk; strength: 20mg/2mL
Recorded listing: General benefit
Source prices (unrounded): $12.7375; ministry $12.7375
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02182947
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=44261
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02182947
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Methotrexate Subcutaneous: Formulary list price $17.5000/unit (unit not stated in source; not the patient's cost)
Ministry pays: $17.5000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98134 · Verify on the e-Formulary ↗ (DIN 02491346)
Source record
DIN 02491346: Methotrexate Subcutaneous
Raw flags: sec3=Y
Item: 100000276; group id 175; item number 0313; lccId None; manufacturer id ACH
Source form: Inj Sol-Pref Syr; strength: 20mg/0.4mL
Recorded listing: General benefit
Source prices (unrounded): $17.5000; ministry $17.5000
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02491346
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98134Interchangeable products
Metoject Subcutaneous · DIN 02454866 · $17.5000
PMS-Methotrexate Injection · DIN 02539640 · $17.5000
Shortage status: resolved shortage (ended 2025-11-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02491346
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Metoject Subcutaneous: Formulary list price $17.5000/unit (unit not stated in source; not the patient's cost)
Ministry pays: $17.5000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94163 · Verify on the e-Formulary ↗ (DIN 02454866)
Source record
DIN 02454866: Metoject Subcutaneous
Raw flags: sec3=Y
Item: 100000276; group id 175; item number 0313; lccId None; manufacturer id MDX
Source form: Inj Sol-Pref Syr; strength: 20mg/0.4mL
Recorded listing: General benefit
Source prices (unrounded): $17.5000; ministry $17.5000
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02454866
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94163Interchangeable products
Methotrexate Subcutaneous · DIN 02491346 · $17.5000
PMS-Methotrexate Injection · DIN 02539640 · $17.5000
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02454866
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Methotrexate Injection: Formulary list price $17.5000/unit (unit not stated in source; not the patient's cost)
Ministry pays: $17.5000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102839 · Verify on the e-Formulary ↗ (DIN 02539640)
Source record
DIN 02539640: PMS-Methotrexate Injection
Raw flags: sec3=Y
Item: 100000276; group id 175; item number 0313; lccId None; manufacturer id PMS
Source form: Inj Sol-Pref Syr; strength: 20mg/0.4mL
Recorded listing: General benefit
Source prices (unrounded): $17.5000; ministry $17.5000
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02539640
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102839Interchangeable products
Methotrexate Subcutaneous · DIN 02491346 · $17.5000
Metoject Subcutaneous · DIN 02454866 · $17.5000
Shortage status: resolved shortage (ended 2025-11-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02539640
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Methotrexate Tablets · DIN 02553740 · 10mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Methotrexate Tablets · DIN 02553740
Manufacturer: Jamp Pharma Corporation; listing date 2025-08-29
Health Canada: Marketed since 2025-06-10 · brand JAMP METHOTREXATE TABLETS · ATC L01BA01 METHOTREXATE · form Tablet · route Oral · ingredients METHOTREXATE 10 MG · company Jamp pharma corporation · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104265 · Verify on the e-Formulary ↗ (DIN 02553740)
Source record
DIN 02553740: Jamp Methotrexate Tablets
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 100000205; group id 175; item number 0317; lccId None; manufacturer id JPC
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $2.3789; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02553740
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104265Interchangeable products
Auro-Methotrexate Tablets · DIN 02448165 · not recorded
Methotrexate Tablets, USP · DIN 02182750 · not recorded
PMS-Methotrexate Tablets · DIN 02561956 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02553740
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Methotrexate Tablets, USP · DIN 02182750 · 10mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Methotrexate Tablets, USP · DIN 02182750
Manufacturer: Pfizer Canada Inc.; listing date 2025-08-29
Health Canada: Marketed since 2017-08-17 · brand METHOTREXATE TABLETS, USP · ATC L01BA01 METHOTREXATE · form Tablet · route Oral · ingredients METHOTREXATE 10 MG · company Pfizer canada ulc · schedule Prescription
Methotrexate Tablets, USP: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42842 · Verify on the e-Formulary ↗ (DIN 02182750)
Source record
DIN 02182750: Methotrexate Tablets, USP
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 100000205; group id 175; item number 0317; lccId None; manufacturer id PFI
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02182750
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42842Interchangeable products
Auro-Methotrexate Tablets · DIN 02448165 · not recorded
Jamp Methotrexate Tablets · DIN 02553740 · not recorded
PMS-Methotrexate Tablets · DIN 02561956 · not recorded
Shortage status: active shortage (reported not recorded, last updated 2024-10-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02182750
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Methotrexate Tablets · DIN 02561956 · 10mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Methotrexate Tablets · DIN 02561956
Manufacturer: Pharmascience Inc.; listing date 2026-01-30
Health Canada: Marketed since 2025-11-28 · brand PMS-METHOTREXATE TABLETS · ATC L01BA01 METHOTREXATE · form Tablet · route Oral · ingredients METHOTREXATE 10 MG · company Pharmascience inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106487 · Verify on the e-Formulary ↗ (DIN 02561956)
Source record
DIN 02561956: PMS-Methotrexate Tablets
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 100000205; group id 175; item number 0317; lccId None; manufacturer id PMS
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $2.3789; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02561956
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106487Interchangeable products
Auro-Methotrexate Tablets · DIN 02448165 · not recorded
Jamp Methotrexate Tablets · DIN 02553740 · not recorded
Methotrexate Tablets, USP · DIN 02182750 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02561956
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered
Matched class: 10:00 ANTINEOPLASTIC AGENTS
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE
Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE
10:00 ANTINEOPLASTIC AGENTS
· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 10:00
and 34 more
Full class listing
Related classes:
Same formulary class, not same indication: class membership alone does not establish equivalent uses.Other drugs whose Health Canada label lists a similar indication: neoplastic diseases, psoriasis, psoriatic arthritis, rheumatoid arthritis
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
Covered without a code on the Ontario formulary: ACITRETIN
BIMEKIZUMAB · Limited Use, codes 641
Indications
Bimzelx (bimekizumab injection) is indicated for:
• Psoriasis (PsO)
The treatment of moderate to severe plaque psoriasis in adult patients who are candidates for
systemic therapy or phototherapy.
PM: https://pdf.hres.ca/dpd_pm/00082779.PDF; date 2025-12-12; DIN 02525267; fetched 2026-09-10
Product monograph
• Psoriasis (PsO)
The treatment of moderate to severe plaque psoriasis in adult patients who are candidates for
systemic therapy or phototherapy.
PM: https://pdf.hres.ca/dpd_pm/00082779.PDF; date 2025-12-12; DIN 02525267; fetched 2026-09-10
Product monograph
• Psoriatic arthritis (PsA)
The treatment of adult patients with active psoriatic arthritis. Bimzelx can be used alone or in
combination with a conventional non-biologic disease-modifying antirheumatic drug (cDMARD)
(e.g., methotrexate).
PM: https://pdf.hres.ca/dpd_pm/00082779.PDF; date 2025-12-12; DIN 02525267; fetched 2026-09-10
Product monographACITRETIN · General benefit
1 INDICATIONS
SORIATANE (acitretin) is indicated for:
• Severe psoriasis (includes erythrodermic and pustular types)
• Other disorders of keratinization
Severe psoriasis is a condition that involves more than 10% of body surface area or is physically,
occupationally or psychologically disabling.
PM: https://pdf.hres.ca/dpd_pm/00080165.PDF; date APR 04, 2025; DIN 02070847; fetched 2026-09-10
Product monographADALIMUMAB · Limited Use, codes 600, 601, 602, 603, 604, 605, 606, 607, 609, 611 (23), Limited Use, codes 600, 602, 603, 604, 605, 606, 607, 609, 633, 634 (7)
Indications
AMGEVITA is indicated for:
Rheumatoid Arthritis
• reducing the signs and symptoms, inducing major clinical response and clinical remission,
inhibiting the progression of structural damage and improving physical function in adult
patients with moderately to severely active rheumatoid arthritis (RA).
PM: https://pdf.hres.ca/dpd_pm/00085868.PDF; date not captured; DIN 02459299; fetched 2026-09-10
Product monographAPREMILAST · Off-Formulary Interchangeable, not an ODB benefit
Indications
• Plaque Psoriasis
OTEZLA (apremilast) is indicated for the treatment of adult patients with moderate to
severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
PM: https://pdf.hres.ca/dpd_pm/00084256.PDF; date 2026-04-10; DIN 02434318; fetched 2026-09-10
Product monographBARICITINIB · Limited Use, codes 615, 734 (1), Limited Use, codes 734 (1)
1 INDICATIONS
OLUMIANT (baricitinib tablets) is indicated for:
Rheumatoid Arthritis (RA)
• In combination with methotrexate (MTX), for reducing the signs and symptoms of moderate
to severe rheumatoid arthritis (RA) in adult patients who have responded inadequately to
one or more disease-modifying anti-rheumatic drugs (DMARDs).
PM: https://pdf.hres.ca/dpd_pm/00074394.PDF; date not captured; DIN 02480018; fetched 2026-09-10
Product monographCYCLOSPORINE · Off-Formulary Interchangeable, not an ODB benefit (2), General benefit (8)
Psoriasis
NEORAL capsules and oral solution (cyclosporine) are indicated for the treatment of severe psoriasis in
patients for whom conventional therapy is ineffective or inappropriate.
PM: https://pdf.hres.ca/dpd_pm/00085584.PDF; date 2026-07-30; DIN 02150662; fetched 2026-09-10
Product monographETANERCEPT · Limited Use, codes 512, 513, 514, 563, 591 (3), Limited Use, codes 498, 499, 514, 563, 591 (4)
• treatment of adult patients with chronic moderate to severe plaque psoriasis (PsO) who are
candidates for systemic therapy or phototherapy.
PM: https://pdf.hres.ca/dpd_pm/00083562.PDF; date August 31, 2016; DIN 02455323; fetched 2026-09-10
Product monographHYDROCORTISONE · General benefit (6), Temporary benefit (1), Listed, not a benefit (2)
• Neoplastic Diseases: For palliative management of: leukemias and lymphomas in adults, acute
leukemia of childhood.
PM: https://pdf.hres.ca/dpd_pm/00082414.PDF; date OCT 20, 2025; DIN 00030910; fetched 2026-09-10
Product monographINFLIXIMAB · Limited Use, codes 468, 469, 470, 471, 477, 478, 479 (2), Limited Use, codes 541, 542, 543, 544, 545, 546, 547 (1), Limited Use, codes 715, 716, 718 (2), Limited Use, codes 592, 593, 594, 595, 596, 597, 598 (1)
• treatment of adult patients with chronic moderate to severe plaque psoriasis who are candidates
for systemic therapy. For patients with chronic moderate plaque psoriasis, RemdantryTM should
be used after phototherapy has been shown to be ineffective or inappropriate. When assessing
the severity of psoriasis, the health professional should consider the extent of involvement,
location of lesions, response to previous treatments, and impact of disease on the patient’s
PM: https://pdf.hres.ca/dpd_pm/00081840.PDF; date September 2, 2025; DIN 02419475; fetched 2026-09-10
Product monographRISANKIZUMAB · Limited Use, codes 574
Indications
SKYRIZI (risankizumab injection) is indicated for:
• the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for
systemic therapy or phototherapy.
PM: https://pdf.hres.ca/dpd_pm/00085642.PDF; date 2026-07-08; DIN 02519283; fetched 2026-09-10
Product monograph
and 2 more
Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS
pms-METHOTREXATE is indicated for Neoplastic diseases:
• Choriocarcinoma: Methotrexate – as single chemotherapy or in combination with other drugs.
• Acute Lymphoblastic Leukemia – as maintenance therapy.
• Head and Neck Cancer – in combination with other chemotherapies.
• Metastasis of unknown primary – as palliative combination chemotherapy.
• Burkitt's lymphoma.
• Advanced stages of childhood lymphoma (III and IV, St. Jude's Childrens’d Research Hospital
Staging System).
• Advanced cases of mycosis fungoides (cutaneous T-cell lymphoma).
pms-METHOTREXATE is indicated as a Disease Modifying Antirheumatic Drug (DMARD) in the
following diseases where standard therapeutic interventions fail:
• Severe disabling psoriasis/psoriatic arthritis
• Severe disabling rheumatoid arthritis (RA)
• Severe disabling seronegative arthritides.
In the treatment of psoriasis, pms-METHOTREXATE should be restricted to severe recalcitrant,
disabling psoriasis, which is not adequately responsive to other forms of therapy, but only when
the diagnosis has been established after dermatologic consultation.
1.1 Pediatrics
Pediatrics (<18 y…
https://pdf.hres.ca/dpd_pm/00078227.PDF
PM date: JAN 08, 2025
Source product: PMS-METHOTREXATE; DIN 02170698; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Methotrexate Tablets, USP · DIN 02182750
Shortage status: active shortage (reported not recorded, last updated 2024-10-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02182750
For Jamp Methotrexate Tablets, Methotrexate Tablets, USP, PMS-Methotrexate Tablets: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.